Unknown

Dataset Information

0

Effect of fenofibrate on uric acid level in patients with gout.


ABSTRACT: Gout is a chronic disease associated with deposition of monosodium urate crystals and accompanied by diabetes, hypertension, and dyslipidemia. Hypertriglyceridemia is common among patients with gout, and fenofibrate is usually used to reduce triglyceride levels. The aim of this study is to determine the effect of uric acid reduction by fenofibrate in patients with gout administered uric acid lowering agents (viz., the xanthine oxidase inhibitors allopurinol and febuxostat). Data from 863 patients with gout were collected from electronic medical records comprising information on underlying diseases, laboratory findings, and drug histories. Among all the patients, 70 (8.11%) took fenofibrate with allopurinol or febuxostat. Male and young patients took fenofibrate more frequently, and hypertension was less frequent in patients administered xanthine oxidase inhibitors and fenofibrate than in those administered only xanthine oxidase inhibitors. After the treatment, serum uric acid levels more significantly decreased (-1.81?±?2.41 vs. -2.40?±?2.28?mg/dL, p?=?0.043) in patients with fenofibrate cotreatment, than in those administered allopurinol or febuxostat alone. The effect of uric acid reduction was larger (b?=?-1.098, p?

SUBMITTER: Jung JY 

PROVIDER: S-EPMC6233215 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of fenofibrate on uric acid level in patients with gout.

Jung Ju-Yang JY   Choi Young Y   Suh Chang-Hee CH   Yoon Dukyong D   Kim Hyoun-Ah HA  

Scientific reports 20181113 1


Gout is a chronic disease associated with deposition of monosodium urate crystals and accompanied by diabetes, hypertension, and dyslipidemia. Hypertriglyceridemia is common among patients with gout, and fenofibrate is usually used to reduce triglyceride levels. The aim of this study is to determine the effect of uric acid reduction by fenofibrate in patients with gout administered uric acid lowering agents (viz., the xanthine oxidase inhibitors allopurinol and febuxostat). Data from 863 patient  ...[more]

Similar Datasets

| S-EPMC6099238 | biostudies-literature
| S-EPMC6832126 | biostudies-literature
| S-EPMC4311063 | biostudies-literature
| S-EPMC4998435 | biostudies-literature
| S-EPMC8566261 | biostudies-literature
| S-EPMC9806969 | biostudies-literature
| S-EPMC9740613 | biostudies-literature
| S-EPMC6335706 | biostudies-literature
| S-EPMC7371161 | biostudies-literature
| S-EPMC10022423 | biostudies-literature